Background
metabolic syndrome, MetS, T2DM
METABOLIC SYNDROME, INSULIN RESISTANCE, TYPE 2 DIABETES MELLITUS
To evaluate the glycemic control effects of vhiglitazar (carfloglitazar), a novel peroxisome proliferator‐activated receptor pan‐agonist, in patients with type 2 diabetes mellitus (T2DM) with metabolic syndrome (MetS) or insulin resistance (IR) using pooled data analysis of two phase III clinical trials.